Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat

Journal of Cardiovascular Pharmacology
Y Erlich, T Rosenthal

Abstract

The contribution of nondegraded bradykinin to the metabolic effects of the angiotensin-converting enzyme (ACE)-kininase II inhibitor ramipril was evaluated in rats rendered hypertensive, hyperinsulinemic, and hypertriglyceridemic by a fructose-enriched diet. The response of blood pressure, insulin, and triglyceride levels to concomitant administration of ramipril and the bradykinin antagonist HOE 140 was studied. Rats that received ramipril, HOE 140, or not treated at all served as controls. Treatment with ramipril reduced levels of both insulin (from 6.6 +/- 2.0 to 3.6 +/- 1.7 ng/ml; p < 0.05) and triglycerides (from 292 +/- 88 to 164 +/- 35 mg/dl; p < 0.001) as well as blood pressure (from 144 +/- 6 to 116 +/- 6 mm Hg; p < 0.001). In contrast, treatment with HOE 140 did not alter any of these parameters. The combined treatment, however, blunted the beneficial metabolic effects of ramipril on insulin (7.8 +/- 4.4 ng/ml before and 7.7 +/- 2.9 ng/ml after treatment) and triglycerides (290 +/- 135 mg/dl before and 285 +/- 152 mg/dl after treatment), whereas the hypotensive effect of ramipril was preserved (151 +/- 8 mm Hg before and 122 +/- 6 mm Hg after treatment (p < 0.001). The data suggest that whereas the hypotensive effect ...Continue Reading

References

Feb 12, 1992·Molecular and Cellular Biochemistry·M Lachaal, C Y Jung
Mar 1, 1991·American Journal of Hypertension·P A Kerth, P M Vanhoutte
Oct 1, 1990·Hypertension·L DanckwardtT Unger
Jun 1, 1989·The American Journal of Clinical Nutrition·A W ThorburnE W Kraegen
Jan 1, 1986·Advances in Experimental Medicine and Biology·A A JaffaG S Bailey
Oct 1, 1987·European Journal of Clinical Investigation·K W JauchG Dietze
Feb 1, 1988·Metabolism: Clinical and Experimental·K W JauchB Günther
Nov 1, 1987·Hypertension·I S HwangG M Reaven
Nov 1, 1982·Metabolism: Clinical and Experimental·I ZavaroniG M Reaven
Jan 1, 1993·Journal of Cardiovascular Pharmacology·P M VanhoutteJ V Mombouli
Jun 1, 1994·Hypertension·N E RhalebO A Carretero
Feb 1, 1995·Metabolism: Clinical and Experimental·E J Henriksen, S Jacob
Jul 1, 1996·Clinical and Experimental Hypertension : CHE·S ChenS Katayama
Aug 1, 1996·Clinical and Experimental Hypertension : CHE·S N IyerM J Katovich
Feb 1, 1996·Clinical and Experimental Hypertension : CHE·K ShimamotoO Iimura
Jan 1, 1995·Clinical and Experimental Pharmacology & Physiology. Supplement·Y Erlich, T Rosenthal

❮ Previous
Next ❯

Citations

Jun 20, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Paul Ernsberger, Richard J Koletsky
Nov 13, 2001·British Journal of Pharmacology·J DamasP J Lefebvre
Jul 3, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·B KennonJ M Connell
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·B Kennon, J M Connell
Mar 19, 2013·Future Medicinal Chemistry·Sven RufThorsten Sadowski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.